Having established that LEM can target PD-L1 in tumor cells and promote an immunotherapeutic effect in vivo, we next asked whether this strategy may potentiate immunotherapeutic effects in the context of anti–CTLA-4 therapy. The gene discussed is CD274; the disease is neoplasm.